Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Amgen Foundation Pledges Up To $5 Million To Hurricane Maria Relief Efforts

Amgen (NASDAQ:AMGN) today announced that the Amgen Foundation has pledged $3 million to support urgent Hurricane Maria relief efforts in Puerto Rico. The Foundation also has committed up to an additional...

AMGN : 185.76 (-0.47%)
4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid

Though the biotech industry is doing well, it's a good idea to avoid a few stocks in the industry which will not prove to be prudent additions to your portfolio.

URGN : 30.49 (+3.32%)
ABEO : 14.95 (-7.72%)
CLSD : 8.30 (+1.84%)
RETA : 31.75 (+0.41%)
NVS : 86.16 (+1.44%)
GILD : 83.27 (+0.79%)
RHHBY : 32.0200 (-0.06%)
KITE : 179.30 (-0.04%)
AMGN : 185.76 (-0.47%)
Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake

Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.

JNJ : 131.39 (-0.27%)
MRK : 65.13 (-0.72%)
AMGN : 185.76 (-0.47%)
PFE : 35.96 (-0.03%)
AMGEN (AMGN) ALERT: Johnson Fistel Announces Investigation of Amgen Inc.; Investors that Bought Before March 17, 2017, Encouraged to Contact the Firm

SAN DIEGO , Sept. 20, 2017 /PRNewswire/ -- Johnson Fistel, LLP, a shareholder rights law firm, is investigating potential claims on behalf of investors of Amgen Inc. (NASDAQ: AMGN) ("Amgen"). Amgen...

AMGN : 185.76 (-0.47%)
AMGEN (AMGN) ALERT: Johnson Fistel Announces Investigation of Amgen Inc.; Investors that Bought Before March 17, 2017, Encouraged to Contact the Firm

Johnson Fistel, LLP, a shareholder rights law firm, is investigating potential claims on behalf of investors of Amgen Inc. (NASDAQ: AMGN) ("Amgen"). Amgen discovers, develops, manufactures, and delivers...

AMGN : 185.76 (-0.47%)
Sucampo Pharmaceuticals Appoints Alex Driggs as General Counsel

Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced the appointment of Alex Driggs to General Counsel and Corporate Secretary. Mr. Driggs joined Sucampo...

SCMP : 11.80 (-0.42%)
AMGN : 185.76 (-0.47%)
Novartis Poised to Grow on Oncology Portfolio & Biosimilars

Novartis expects the next growth phase to begin in 2018 driven by Cosentyx Entresto, Kisqali and Kymriah.

NVS : 86.16 (+1.44%)
RHHBY : 32.0200 (-0.06%)
AMGN : 185.76 (-0.47%)
ALXN : 142.82 (-0.07%)
deCODE Study Reveals an Ancient Achilles Heel in the Human Genome

REYKJAVIK, Iceland, September 20, 2017 /PRNewswire/ --

AMGN : 185.76 (-0.47%)
deCODE Study Reveals an Ancient Achilles Heel in the Human Genome

-- The generation of new mutations is a key driver of evolution but also of susceptibility to rare diseases

AMGN : 185.76 (-0.47%)
deCODE Study Reveals an Ancient Achilles Heel in the Human Genome

REYKJAVIK, Iceland , September 20, 2017 /PRNewswire/ --

AMGN : 185.76 (-0.47%)
Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook

Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.

VRTX : 151.26 (-0.53%)
BMRN : 94.95 (+1.64%)
ABBV : 87.48 (+0.08%)
TSRO : 119.04 (+0.31%)
NBRV : 8.47 (+1.44%)
AMGN : 185.76 (-0.47%)
HALO : 16.78 (+1.08%)
Is Amgen (AMGN) a Great Stock for Value Investors?

Let's see if Amgen Inc. (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.

AMGN : 185.76 (-0.47%)
Cytokinetics Announces Dosing of First Patient in Japan in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure

Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that the first patient has been dosed in Japan in GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility...

CYTK : 14.30 (+0.70%)
AMGN : 185.76 (-0.47%)
Novartis Announces Positive Data on Urticaria Drug Xolair

Novartis AG (NVS) announced new positive data on chronic spontaneous urticaria (CSU) drug Xolair from a phase IIIb study, OPTIMA.

NVS : 86.16 (+1.44%)
RHHBY : 32.0200 (-0.06%)
AMGN : 185.76 (-0.47%)
ADRO : 10.80 (-1.82%)
Arcus Biosciences Appoints Kate Falberg to Its Board of Directors

Arcus Biosciences, a biotechnology company focused on the discovery and development of innovative cancer immunotherapies, today announced the appointment of Kathryn ("Kate") Falberg to its...

AIMT : 23.62 (-1.17%)
URGN : 30.49 (+3.32%)
TTD : 59.80 (+0.44%)
AXON : 24.99 (-4.18%)
AMGN : 185.76 (-0.47%)
Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA 21st Annual Scientific Meeting

Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating...

CYTK : 14.30 (+0.70%)
AMGN : 185.76 (-0.47%)
Genentech Receives Blow by FDA in Cancer Drug Avastin Biosimilar Battle, an Industrial Info News Alert

Researched by Annette Kreuger, Industrial Info Resources --Biological drug maker Genentech, the developer of the blockbuster cancer drug Avastin, was dealt a stunning blow on September 14 when the U.S....

AMGN : 185.76 (-0.47%)
Top Research Reports for Philip Morris, Amgen & Union Pacific

Top Research Reports for Philip Morris, Amgen & Union Pacific

UNP : 115.34 (-0.09%)
AFL : 83.94 (+0.37%)
UTX : 115.01 (+0.45%)
ORCL : 48.16 (+0.40%)
PM : 112.51 (-0.36%)
AMGN : 185.76 (-0.47%)
Amgen/Allergan's Avastin Biosimilar Secures FDA Approval

The FDA approves Amgen-Allergan's biosimilar version of Roche's Avastin for treating multiple types of cancers, to be marketed by the trade name of Mvasi.

JNJ : 131.39 (-0.27%)
AGN : 204.65 (+0.98%)
RHHBY : 32.0200 (-0.06%)
AMGN : 185.76 (-0.47%)
New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

Amgen (NASDAQ:AMGN) today announced that a new analysis of the cardiovascular outcomes study (FOURIER) demonstrated that lowering low-density lipoprotein cholesterol (LDL-C) levels with Repatha® (evolocumab)...

AMGN : 185.76 (-0.47%)

Van Meerten Stock Picks

5 Great Mid Caps
Today I wanted to find 5 Mid Cap stocks that had a high gain over the last year and continue to have current momentum.
DAN +0.41 , IPGP +4.16 , TEX -0.46 , NVR +29.06 , TTWO +1.12
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ17 -0.14% ) this morning are down -0.09% on heightened North Korean tensions after North Korean President Kim Jong Un promised the "highest level of hardline" countermeasures against the U.S.... Read More

Chart of the Day

Chart of the Day

Fiat Chrysler Automobiles (FCAU) is the Barchart Chart of the Day.  The international auto producer has a Trend Spotter buy signal, a Weighted Alpha of 190.70+ and gained 174.92% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures settled Friday with 2 to 3 1/2 cent gains, as Dec was 1 1/4 cent lower on the week. Rains over the next week could slow corn harvest in most of the WCB. Next Friday at 11:00 a.m. will be the release of the Sept 1 Grain Stocks report. The...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.